Natural killer (NK)/T-cell Lymphomas – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Natural killer (NK)/T-cell lymphomas are aggressive cancers that are classified as nasal, non-nasal, and disseminated subtypes. Nasal NK/T-cell lymphomas affect the nasal cavity as well as the upper aerodigestive tract. Skin, testis, gastrointestinal tract, and other extranodal sites are all affected by non-nasal NK/T-cell lymphomas. Disseminated NK/T-cell lymphoma affects multiple organs and rarely presents with a leukemic phase. CD3 (not surface CD3), cytotoxic molecules, CD56, and EBV-encoded small RNA are all found in lymphoma cells. Natural killer (NK) cells arise from a common lymphoid progenitor that can differentiate into all lymphoid lineages. Expression of the transcription regulators STAT5, RUNX3, NOTCH, PU.1, TCF1, NFIL3 and CBFB leads to NK lineage commitment. NK cells are part of the innate immune system and are responsible for detecting and killing tumours or virally infected cells. They are strategically located at mucosal surfaces, the skin and the gut and circulate between the blood and bone marrow. The normal residency of NK cells in these sites accounts for the predominant extranodal localization of malignancies arising from neoplastic NK cells.
·
The incidence of Natural killer (NK)/T-cell
lymphomas ranges from 0.8 to 1.2 of one million population in the USA.
Thelansis’s “Natural killer
(NK)/T-cell Lymphomas Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Natural
killer (NK)/T-cell Lymphomas treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Natural killer (NK)/T-cell Lymphomas across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Natural killer (NK)/T-cell Lymphomas Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment